The Future Of The Biologicals Market: Market Overview, Innovations And Company Profiles
Biopharmaceutical products are the key to the future of the pharmaceutical market
. Even before the market stagnation seen in 2009 due to the recession, conventional pharmaceuticals were facing drastic consequences from the loss of patent cover for many blockbusters, and the continued failure of the R&D departments in big pharma to produce replacement candidates.
Although the conventional, small-molecule segment of the market will continue to hold a larger share, their growth is expected to be in low single figures, while biopharma products are forecast to grow at rates up to 10% per annum.
This report analyses the three main components of the biopharma market monoclonal antibodies, therapeutic proteins and vaccines to show why these groups have such a positive future. It provides the most up-to-date discussion of the whole biopharma market and explores new clinical indications beyond those already targeted.
Key features of this report
Monoclonal antibodies will build on recent market growth as new product candidates come onstream and new indications are confirmed, extending the usefulness of Mabs beyond cancers and autoimmune disease to CNS conditions, infections and others.
The Therapeutic Proteins class will continue to be dominated by hematopoietic growth factor products for cancer-related neutropenia and anemia.
Cytokines are another important contributor to the Therapeutic Proteins sector, and new uses for them are under investigation, including cancers, benign prostatic hyperplasia, gout, wound healing and inflammatory diseases such as Crohns.
Buoyancy in the Vaccines sector is driven by anxiety over bioterrorism, the ongoing risk of a global influenza pandemic and new targets for prevention.
The prospect of therapeutic vaccines, especially against cancers, is another major driver in the vaccines market.
Scope of this report
The report gives a realistic picture of the strengths and limitations of the biopharma marketplace, indicating those product groups whose strengths are set to last while avoiding over-optimistic forecasts of growth over the next five years.
In terms of R&D activity, the report aims to give the reader a perspective on the important research avenues now being pursued, while updating the reader with an overview of recent R&D developments .
By covering all the three major segments of the biopharma market, the report gives a better perspective of the contribution of biopharma to the management of some major diseases than would be gleaned from studying only a single product type.
Key Market Issues
Monoclonal antibodies are forecast to grow at a CAGR approaching 10% over the next five years, driven largely by good results in the clinic
Cancers and immune-related inflammatory diseases will continue to be leading iuses of Mabs during the five-year forecast period
New indications offer the prospect of major market growth for cytokines; these include cancers and inflammatory diseases
Other therapeutic proteins such as growth factors, coagulation factors and erythropoietins, have limited opportunities for growth through excpanding indications, and depend instead on product improvements
Key findings from this report
In terms of market size, therapeutic proteins are the leaders, but monoclonal antibodies (MAbs) are the fastest growing sector
Cancer still ranks high among targets for new MAb development, along with treatments for inflammation/immune related diseases including rheumatoid arthritis and multiple sclerosis
Cytokines in advanced development include treatments for cancers, benign prostatic hyperplasia, gout and inflammatory conditions such as Crohns disease.
By the end of 2009 there were 29 monoclonal antibodies approved and marketed for therapeutic use. This product class is now approaching maturity.
Therapeutic protein products which have been success stories include insulin, erythropoietin, growth hormone, the interferons, and the fusion protein Enbrel (etanercept)
Key questions answered
What indications will be the main market drivers for Mabs during the next five years?
What are the most important market trends in the vaccines market?
Will the biopharma market perform any better than the overall pharma market during the next five years, and why?
Which segments of the therapeutic protein market are likely to see the best growth?
What are the major drivers for M&A activity in the biopharma market?
To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/3856/The-Future-of-the-Biologicals-Market-Market-overview-innovations-and-company-profiles.html
Contact us:
Visionshopsters
Ph : 91-22-40583020
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com
by: Visionshopsters
How Social Media Can Help Ottawa Advertisers & Ottawa Marketers The Elements of Various Marketing Tools That You Should Know About PPC Marketing vs. Article Marketing Are You Committing These Mistakes While Using Marketing Tools? How To Choose The Best Program To Market How To Use Joint Venture Marketing To Increase Website Traffic Instant Spyware Removal Review Is It A Scam? Volatility In Investment Market And Currency Exchange Remains A Challenge Become An Online Marketing Success Earn Profit: Are you losing money? E-Commerce - Affiliate Marketing starting off in the world of E-Commerce online Marketing - Affiliate Marketing Site Helps Connect Affiliates With Affiliate Managers New Report on "Venezuela Gas Markets Investment Opportunities, Market Analysis and Forecasts to 2020" added in Vision Shopsters
The Future Of The Biologicals Market: Market Overview, Innovations And Company Profiles Anaheim